CIBC Private Wealth Group
ASBP

CIBC Private Wealth Group’s Aspire Biopharma ASBP Stock Holding History

CIBC Private Wealth Group’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.48K Hold
41
– – ﹤0.01% 2565
2025
Q3 		$10.1K Buy
41
+35
+583% +$17.5K ﹤0.01% 2382
2025
Q2 		$1.91K Buy
+6
New +$2.85K ﹤0.01% 2649

Other funds holding ASBP

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
RA
Resolute Advisors San Francisco, California $242M AUM 52.95% 1-Year Est. Return

CIBC Private Wealth Group's ASBP Position: Q4 2025 in Review

CIBC Private Wealth Group held its Aspire Biopharma (ASBP) position steady in Q4 2025 at 41 shares worth $6.48K. The position accounts for ﹤0.01% of the portfolio, ranked #2565.

CIBC Private Wealth Group first reported a position in ASBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $10.1K in Q3 2025. 28 funds tracked by Wall St. Rank hold ASBP as of Q4 2025.

  • CIBC Private Wealth Group held 41 shares of Aspire Biopharma worth $6.48K as of Q4 2025.
  • CIBC Private Wealth Group left its Aspire Biopharma share count unchanged in Q4 2025.
  • Aspire Biopharma made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2565 holding.
  • CIBC Private Wealth Group first reported a position in Aspire Biopharma in Q2 2025 and has held it in 3 quarters since.
  • CIBC Private Wealth Group's Aspire Biopharma position peaked at $10.1K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Aspire Biopharma as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.